Copied
 
 
Formål
Formål
Kommanditselskabets formål er at eje (direkte eller indirekte) rettigheder i eller til medicinske produkter, herunder IP rettigheder, eller til royalty betalinger, milestone betalinger og andre betalinger hidrørende fra sådanne produkter. Kommanditselskabets formål er endvidere at indgå kontrakter relateret til sådanne medicinske produkter, IP rettigheder og/eller økonomiske rettigheder.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 11.12.2014 (3426 dage).
Ingen historik.
Status
Virksomhedsstatus
NORMAL.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 15.10.2014 (3483 dage).
Ingen historik.
Branche
Branche
Forskning og eksperimentel udvikling indenfor bioteknologi (721100).
Sidst opdateret den 16.01.2015 og angivet som gældende fra 15.10.2014 (3483 dage).
Ingen historik.
Revision
Revisionfravalgt
false.
Sidst opdateret den 11.03.2015 og angivet som gældende fra 15.10.2014 (3483 dage).
Ingen historik.
Revisor
Revisor
EY Godkendt Revisionspartnerselskab
Sidst opdateret den 27.05.2021 og angivet som gældende fra 30.04.2020 (1459 dage).
Form
Virksomhedsform
40.
Sidst opdateret den 15.10.2014 og angivet som gældende fra 15.10.2014 (3483 dage).
Ingen historik.
Kontakt
Kontaktoplysninger
info@zealandpharma.com.
Sidst opdateret den 04.09.2019 og angivet som gældende fra 04.09.2019 (1698 dage).
Ingen historik.
Telefon
Ingen nuværende registrering.
Ingen historik.
Navne
Ingen historik.
Tegningsregel
Tegningsregel
Kommanditselskabet tegnes af komplementaren.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 11.12.2014 (3426 dage).
Fortolkning (1 tegningsmulighed)
komplementaren
Ingen historik.
Ansatte
28.04.2024
Ingen historik.
Kapital
28.04.2024
Ingen historik.
Fra årsrapport
Type af revisorbistand:Auditor's report on audited financial statements
Navn på revisionsvirksomhed:EY Godkendt Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:30700228
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Reporting class B
Grundlag for konklusion (revision):Basis for opinionWe conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. IndependenceWe are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.
Konklusion (revision):OpinionWe have audited the financial statements of ZP SPV 1 K/S for the financial year 1 January - 31 December 2023, which comprise income statement, balance sheet and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2023 and of the results of the Company's operations for the financial year 1 January 2023 - 31 December 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on the Management's review Management is responsible for the Management's review. Our opinion on the financial statements døs not cover the Management's review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Management's review.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
28.04.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
28.04.2024
Ingen nuværende registrering.
Ingen historik.